Eloxx Pharmaceuticals
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
PO Box 274, Arlington, Massachusetts, 02...Phone Number
(781) 577-5300Website
www.eloxxpharma.comRevenue
-Stock Symbol
ELOXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, with research operations in Rehovot, Israel. The company develops RNA-modulating, ribosome-targeted therapies for rare and ultra-rare genetic diseases caused by premature stop codon mutations. Its lead candidate, exaluren, is being developed for Alport syndrome and other kidney diseases associated with nonsense mutations. Eloxx has also licensed a related compound to a global pharmaceutical partner for development in rare skin diseases.Explore more
Eloxx Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Eloxx Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Eloxx Pharmaceuticals recently announced quarterly report
Click to see if Eloxx Pharmaceuticals had a recent Job posting/layoffs
Check if Eloxx Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Eloxx Pharmaceuticals has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Eloxx Pharmaceuticals launches new products
Eloxx Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Eloxx Pharmaceuticals
Check out if Eloxx Pharmaceuticals is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Eloxx Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Eloxx Pharmaceuticals
Compare insights from companies similar to Eloxx Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Eloxx Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Eloxx Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Eloxx Pharmaceuticals.
Eloxx Pharmaceuticals financials insights
Gather financial insights about Eloxx Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
2022
Other Financing Round
$15.9M
2024
Debt
$3.2M
Eloxx Pharmaceuticals Tech Stack
A closer look at the technologies used by Eloxx Pharmaceuticals
See more technologies
Most Recent Scoops
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Eloxx Pharmaceuticals News & Media
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third...Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq
ARLINGTON, Mass., June 8, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) ("Eloxx" and the "Company"), a clinical-stage biopharmaceutical company developing novel, small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop...National defense takes center stage as U.S. shipyards rebuild capacity - WorkBoat
U.S. shipbuilding surges with DoD funding, policy shifts, and autonomous vessels as shipyards scale production and rebuild workforce capacity.Eloxx Pharmaceuticals Announces Key Corporate Accomplishments
Data from Eloxx’s proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Eloxx Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, with research operations in Rehovot, Israel. The company develops RNA-modulating, ribosome-targeted therapies for rare and ultra-rare genetic diseases caused by premature stop codon mutations. Its lead candidate, exaluren, is being develop... Read More
